Scotiabank upgraded Legend Biotech to Outperform from Sector Perform with a $65 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech Reports Preliminary Sales Surge
- Legend Biotech’s CARVYKTI® Revolutionizes Multiple Myeloma Treatment
- Legend’s CARVYKTI approved by FDA for second-line treatment of multiple myeloma
- Cantor starts Legend Biotech at Overweight on Carvykti expansion
- Legend Biotech initiated with an Overweight at Cantor Fitzgerald